On May 24, 2017 Sierra Oncology, Inc. (NASDAQ: SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer, reported that it will be presenting two Trials in Progress posters describing the innovative Phase 1 clinical designs for its Chk1 inhibitor, SRA737, at the 2017 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, being held in Chicago on June 5th (Press release, Sierra Oncology, MAY 24, 2017, View Source [SID1234519282]). These ongoing trials were recently amended to include cohort expansions of prospectively selected patients with tumors identified to have genetic aberrations hypothesized to confer sensitivity to Chk1 inhibition via synthetic lethality. Schedule your 30 min Free 1stOncology Demo! The company also announced that Dr. Nick Glover, President and Chief Executive Officer of Sierra Oncology, will present an overview of the company entitled "Beyond PARP – Next Generation DDR Therapeutics" at the Jefferies Healthcare Conference in New York. The presentation is scheduled for 2:00pm ET on June 8th. A live audio webcast and archive of the presentation will be accessible through www.sierraoncology.com.
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
ASCO 2017 Poster Presentations
Title: A phase I study of SRA737 (formerly known as CCT245737) administered orally in patients with advanced cancer.
Trials in Progress Abstract: #TPS2607
Poster: #93b
Poster Session: Developmental Therapeutics — Clinical Pharmacology and Experimental Therapeutics
Date and Time: Monday, June 5, 2017, 8:00 – 11:30am CT
Location: McCormick Place, Event room: Hall A, 2301 S King Dr., Chicago, Illinois
Title: A phase I study of oral SRA737 (formerly CCT245737) given in combination with gemcitabine plus cisplatin or gemcitabine alone in patients with advanced cancer.
Trials in Progress Abstract: #TPS2613
Poster: #96b
Poster Session: Developmental Therapeutics — Clinical Pharmacology and Experimental Therapeutics
Date and Time: Monday, June 5, 2017, 8:00 – 11:30am CT
Location: McCormick Place, Event room: Hall A, 2301 S King Dr., Chicago, Illinois
The posters will be available on June 5, 2017 on the company’s website at www.sierraoncology.com
Jefferies Healthcare Conference
Title: Beyond PARP – Next Generation DDR Therapeutics
Date and Time: June 8, 2017, 2:00 pm ET
Live audio webcast and archive of the presentation will be accessible through www.sierraoncology.com.